Abstract Library

#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis

Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,

Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,

#2999 Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours

Introduction: Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Blazevic A

Authors: Blazevic A, Iyer A, Van Velthuysen M, Hofland J, Franssen G,

Keywords: Small-intestinal neuroendocrine tumors, mesenteric fibrosis, serotonin, tryptophan metabolism, proteomics,

#2995 Prediction of Symptomatic Mesenteric Mass in Patients with Small Intestinal Neuroendocrine Tumors Using a CT Radiomics Approach

Introduction: A mesenteric mass surrounded by fibrosis is a hallmark feature of small intestinal neuroendocrine tumors (SI-NETs) that can induce severe abdominal complications. To improve clinical outcome, there is a need for personalized treatment strategies based on accurate prediction of development of abdominal complications.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Blazevic A

Authors: Blazevic A, Starman M, Brabander T, Hofland J, Franssen G,

Keywords: Small-intestinal neuroendocrine tumors, mesenteric mass, mesenteric fibrosis, radiomics, CT scan,

#2095 Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors

Introduction: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the development of a SI-NET associated mesenteric mass over time.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Feelders R, Hofland J, Franssen G, Van Velthuysen M,

Keywords: Small intestinal neuroendocrine tumor, Mesenteric metastasis, Radiology, Peptide receptor radionuclide therapy,

#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Zandee W, Franssen G, Hofland J, Van Velthuysen M,

Keywords: Small intestinal neuroendocrine tumors, Palliative surgery, Prognosis,